

# BioSpect

the business of Bio

24 years of leveraging the business of Bio  
[www.biospectrumindia.com](http://www.biospectrumindia.com)

**#startup of the day 28 - Litemed India**

12 October 2026 | Features

**Advancing Product Innovation and Global Expansion**



**Inception** - 2022

**Location** - Hyderabad, Telangana

**Industry domain** - HealthTech | MedTech | Wearable Medical Devices | Pain Management | Women's Health

**Founders** - Sri Velliyur – Co-Founder & CEO, Surya Maguluri – Founder & Chief Technology Officer

**Total Team Strength** - 38

**Total funds raised** - ₹120 crore – Pre-Series A

**Investors** - V3, 3I and Ideaspring

**Revenue Generated Since Inception** - 2.15 crore

**Key Highlights / Achievements in 2025–26 -**

1. Raised ₹120 crore in Pre-Series A funding, led by V3, 3I and Ideaspring.
2. Expanded CURAPOD's presence to 20,000+ users across PAN India, as per the company profile.
3. Built a wearable medical-device platform focused on personalised, non-invasive and drug-free pain management.
4. CURAPOD is designed to address 30+ musculoskeletal conditions.
5. Technology has undergone double-blind, randomised, placebo-controlled, multicentre clinical validation.
6. Expanded engagement with physiotherapy practices, wellness centres and clinical networks.
7. Launched CURAPOD M, extending the company's technology platform into menstrual pain management and women's health.
8. Funding is being deployed towards R&D, product and app development, clinical adoption, manufacturing, D2C expansion, branding and marketing, and international expansion.
9. Preparations are underway for international expansion, including Europe.

**Founder Speaks -**

CURAPOD aims to scale its presence across India while expanding its manufacturing and supply-chain capabilities and strengthening its direct-to-consumer (D2C) and marketplace distribution channels. The company plans to deepen partnerships with clinicians and physiotherapists, continue product and app innovation, and introduce software upgrades and AI-driven therapy insights based on real-world data. It also intends to expand its wearable medical-device portfolio, including applications in women's health, while exploring international markets, particularly Europe and the USA, as part of its future growth strategy.

- **Surya Maguluri**